Brendle Madeline, Ahuja Sachin, Valle Maisa Della, Moore Claire, Thielking Paul, Malone Daniel C, Robison Reid
Department of Pharmacotherapy, University of Utah College of Pharmacy, UT 84112, USA.
Numinus Wellness, UT 84020, USA.
J Comp Eff Res. 2022 Dec;11(18):1323-1336. doi: 10.2217/cer-2022-0149. Epub 2022 Nov 4.
There is limited real-world evidence for patients with treatment-resistant depression (TRD) receiving esketamine nasal spray. This retrospective cohort study used data collected from a psychiatric clinic's EHR system. A total of 171 TRD patients received esketamine July 2019-June 2021. This predominantly female, white population had several mental health comorbidities and high exposure to psychiatric medications. We observed significant reductions (p < 0.001) in average PHQ-9 and GAD-7 scores from baseline (PHQ-9: mean: 16.7; SD: 5.8; GAD-7: mean: 12.0; SD: 5.8) to last available treatment (PHQ-9: mean: 12.0; SD: 6.4; GAD-7: mean: 8.7; SD: 5.6). There were no reports of serious adverse events. This study found a significant disease burden for patients with TRD. Esketamine appears to be well tolerated and effective in improving depression and anxiety.
对于难治性抑郁症（TRD）患者使用艾氯胺酮鼻喷雾剂，现实世界中的证据有限。这项回顾性队列研究使用了从一家精神科诊所的电子健康记录（EHR）系统收集的数据。共有171名TRD患者在2019年7月至2021年6月期间接受了艾氯胺酮治疗。这个以女性和白人为主的群体存在多种心理健康合并症，且大量接触精神科药物。我们观察到，从基线（PHQ-9：均值：16.7；标准差：5.8；GAD-7：均值：12.0；标准差：5.8）到最后一次可用治疗时，平均PHQ-9和GAD-7评分显著降低（p < 0.001）（PHQ-9：均值：12.0；标准差：6.4；GAD-7：均值：8.7；标准差：5.6）。没有严重不良事件的报告。这项研究发现TRD患者存在显著的疾病负担。艾氯胺酮似乎耐受性良好，并且在改善抑郁和焦虑方面有效。
